Abcuro
Abcuro, Inc.
Precision Targeting of Highly Cytotoxic T Cells in Autoimmune Disease.
abcuro.com · Newton, MA
Funding event
The round itself, as filedInferred stageSeries B
Sold of offered$39.4M of $177M
Filed2026-08-13
Days since filing52
- Exemption claimed
- Rule 506(b)
- First-ever Form D
- No
- Date of first sale
- 2026-08-07
Investors
No investors named: Form D does not list them
Officers on the filing
Names and roles as filed; addresses are never stored- John Alexander MartinExecutive Officer · Director
- Mark PruzanskiDirector
- Ron HuntDirector
- Michael DybbsDirector
- Ming FangDirector
- Sarah BoyceDirector
Health flags
Three flags, each with the raw inputs behind it · as of 2026-10-03UndersubscribedNot flagged22.3% sold1.9 months since first sale
Prior raiseNot flaggedPrior raise not known—
AmendedNot flaggedNo amendmentNo D/A on file
Open roles
On the employer's own careers page · checked 2026-09-230
Pre-posting windowNot enough dataShown once this sector and stage have 20 observed lags from filing to first posting.
No open roles foundWe read careers pages daily.
Also raised in Health & bio
Same sector, 28 days to 2026-10-04Altay TherapeuticsSeries A · $15.7M of $45.1M · San Carlos, CAQuietCarebilitySeries A · $8.8M of $8.8M · Richardson, TXQuiet
75 rounds in Health & bio in the 28 days to 2026-10-03, against 71 in the 28 days before.